Please assess the completion status of the following clinical trial:

Trial Title: Study of Danicopan in Participants With Paroxysmal Nocturnal Hemoglobinuria With Inadequate Response to Eculizumab

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Key Inclusion Criteria:~* Diagnosed with PNH~* Have received at least one red blood cell transfusion within last 12 weeks~* Anemia with adequate reticulocytosis~* Must be on a stable regimen of eculizumab~* Platelet count ≥ 40,000/microliter without the need for platelet transfusions~* Documentation of vaccination for Neisseria meningitidis, Haemophilus influenza, and Streptococcus pneumoniae or willingness to receive vaccinations based on local guidelines~* Willingness to receive antibiotic prophylaxis~* Female participants must use highly effective birth control to prevent pregnancy during the clinical trial and for 30 days after their last dose of study drug~* Male participants must use a highly effective birth control with a female partner to prevent pregnancy during the clinical trial and for 90 days after the last dose of study drug~Key Exclusion Criteria:~* Current evidence of bone marrow failure or aplastic anemia requiring treatment~* History of a major organ transplant or hematopoietic stem cell/marrow transplant~* Received another investigational agent within 30 days or 5 half-lives of the investigational agent prior to study entry, whichever is greater~* Documented C5 complement protein mutations~* Known or suspected complement deficiency~* Contraindication to any of the required vaccinations~* Active bacterial infection or clinically significant active viral infection, a body temperature \>38°C, or other evidence of infection~* History of meningococcal infection, or a first-degree relative or household contact with a history of meningococcal infection~* History of hypersensitivity reactions to commonly used antibacterial agents~Note: Additional inclusion/exclusion criteria may apply, per protocol.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Group 1: 100 mg Danicopan TID + Eculizumab (Type: EXPERIMENTAL): Starting dose of 100 mg danicopan TID in combination with eculizumab.
- Group 2: Initial dose 100 or 150 mg Danicopan TID + Eculizumab (Type: EXPERIMENTAL): Starting dose of 100 or 150 mg danicopan TID in combination with eculizumab.
- Group 3: Initial dose of 100, 150, or 200 mg Danicopan TID + Eculizumab (Type: EXPERIMENTAL): Starting dose of 100, 150, or 200 mg danicopan TID in combination with eculizumab.
- Group 4: Optimal Dose of Danicopan TID + Eculizumab (Type: EXPERIMENTAL): Optimal dose (starting dose of either 100, 150, or 200 mg, as determined from Groups 1-3) of danicopan TID in combination with eculizumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).